-+ 0.00%
-+ 0.00%
-+ 0.00%

SAB Biotherapeutics posts FY 2025 net income of USD 13.27 million as R&D expenses rise 14% to USD 34.35 million

Reuters·03/09/2026 21:11:30

Please log in to view news